A. Sato

发表

Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial

Allan C. deCamp, A. Perelson, E. Giorgi, 2021, Nature Medicine.

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study

Allan C. deCamp, J. Weiner, M. Nussenzweig, 2019, PloS one.

Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity

Daniel E. Zak, D. Zak, A. Aderem, 2012, Proceedings of the National Academy of Sciences.

Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses

S. Self, D. Montefiori, R. Gottardo, 2017, Journal of Virology.

Speci ﬁ city and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modi ﬁ ed Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

S. Hammer, B. Moss, S. Buchbinder, 2014 .

Prospective Surveillance for Cardiac Adverse Events in Healthy Adults Receiving Modified Vaccinia Ankara Vaccines: A Systematic Review

B. Chaitman, D. Lawrence, S. Vasan, 2013, PloS one.

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study

D. Montefiori, R. Gottardo, G. Pantaleo, 2022, Frontiers in Immunology.

3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates

B. Pulendran, B. Haynes, D. Montefiori, 2020, Science Immunology.

Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories

S. Self, P. Kaleebu, R. Koup, 2010, PloS one.

Characterization of T-Cell Responses to Cryptic Epitopes in Recipients of a Noncodon-Optimized HIV-1 Vaccine

P. Goepfert, A. Bansal, A. Sato, 2014, Journal of acquired immune deficiency syndromes.

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap

D. Montefiori, L. Morris, C. Williamson, 2016, Clinical and Vaccine Immunology.

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

Allan C. deCamp, J. Mascola, R. Koup, 2022, Nature Medicine.

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

W. Blattner, B. Moss, D. Montefiori, 2011, The Journal of infectious diseases.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

S. Hammer, B. Moss, D. Montefiori, 2014, The Journal of infectious diseases.

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

D. Montefiori, M. McElrath, L. Corey, 2011, The Journal of infectious diseases.

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection

Jerome H. Kim, Yufei Wang, T. Whittall, 2017, Scientific Reports.

Association between cigarette smoking and colorectal cancer in the Women's Health Initiative.

T. Rohan, M. Allison, E. Paskett, 2007, Journal of the National Cancer Institute.

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

S. Self, D. Montefiori, R. Gottardo, 2016, Journal of Virology.

Streamlining Heterologous DNA-Prime and NYVAC / Protein-Boost HIV Vaccine Regimens in 1 Rhesus Macaques by Employing Improved Antigens 2 3

S. Self, D. Montefiori, R. Gottardo, 2016 .

Title Employing Improved Antigens Allows Streamlining of Heterologous DNA-Prime and NYVAC / Protein-Boost HIV Vaccine Regimens in Rhesus Macaques Running title : Improved HIV Antigens and Delivery Schedules in Macaques

Ralf, Barnett, D. Montefiori, 2015 .

Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials.

Devan V Mehrotra, Peter B Gilbert, Alicia Sato, 2009, Vaccine.

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection

Jerome H. Kim, Yufei Wang, T. Whittall, 2017, Scientific Reports.

Immunoglobulin genes and the acquisition of HIV infection in a randomized trial of recombinant adenovirus HIV vaccine.

James Y. Dai, A. Namboodiri, J. Pandey, 2013, Virology.